Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1182/blood-2017-01-758854 http://scihub22266oqcxt.onion/10.1182/blood-2017-01-758854 C5418639!5418639 !28254742     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28254742 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Blood 2017 ; 129 (18 ): 2570-2580 Nephropedia Template TP {{tp|p=28254742 |t=2017. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-? production |pdf=|usr=}}{{28254742 }} gab.com Text Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF- production JO: Blood http://www.kidney.de/pget.php?&tw=1&pmid=28254742 #FOAvip Allogeneic hematopoietic stem cell transplantation is hampered by chronic graft-versus-host disease (cGVHD), resulting in multiorgan fibrosis and diminished function. Fibrosis in lung and skin leads to progressive bronchiolitis obliterans (BO) and scleroderma, respectively, for which new treatments are needed. We evaluated pirfenidone, a Food and Drug Administration (FDA)-approved drug for idiopathic pulmonary fibrosis, for its therapeutic effect in cGVHD mouse models with distinct pathophysiology. In a full major histocompatibility complex (MHC)-mismatched, multiorgan system model with BO, donor T-cell responses that support pathogenic antibody production are required for cGVHD development. Pirfenidone treatment beginning one month post-transplant restored pulmonary function and reversed lung fibrosis, which was associated with reduced macrophage infiltration and transforming growth factor-? production. Pirfenidone dampened splenic germinal center B-cell and T-follicular helper cell frequencies that collaborate to produce antibody. In both a minor histocompatibility antigen-mismatched as well as a MHC-haploidentical model of sclerodermatous cGVHD, pirfenidone significantly reduced macrophages in the skin, although clinical improvement of scleroderma was only seen in one model. In vitro chemotaxis assays demonstrated that pirfenidone impaired macrophage migration to monocyte chemoattractant protein-1 (MCP-1) as well as IL-17A, which has been linked to cGVHD generation. Taken together, our data suggest that pirfenidone is a potential therapeutic agent to ameliorate fibrosis in cGVHD. Twit Text FOAVip Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF- production ????Blood http://www.kidney.de/pget.php?&tw=1&pmid=28254742 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28254742 #FOAvip English Wikipedia <ref>{{Cite pmid|28254742 }}</ref> Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-? production #MMPMID28254742 Du J ; Paz K ; Flynn R ; Vulic A ; Robinson TM ; Lineburg KE ; Alexander KA ; Meng J ; Roy S ; Panoskaltsis-Mortari A ; Loschi M ; Hill GR ; Serody JS ; Maillard I ; Miklos D ; Koreth J ; Cutler CS ; Antin JH ; Ritz J ; MacDonald KP ; Schacker TW ; Luznik L ; Blazar BR Blood 2017[May]; 129 (18 ): 2570-2580 PMID28254742 show ga Allogeneic hematopoietic stem cell transplantation is hampered by chronic graft-versus-host disease (cGVHD), resulting in multiorgan fibrosis and diminished function. Fibrosis in lung and skin leads to progressive bronchiolitis obliterans (BO) and scleroderma, respectively, for which new treatments are needed. We evaluated pirfenidone, a Food and Drug Administration (FDA)-approved drug for idiopathic pulmonary fibrosis, for its therapeutic effect in cGVHD mouse models with distinct pathophysiology. In a full major histocompatibility complex (MHC)-mismatched, multiorgan system model with BO, donor T-cell responses that support pathogenic antibody production are required for cGVHD development. Pirfenidone treatment beginning one month post-transplant restored pulmonary function and reversed lung fibrosis, which was associated with reduced macrophage infiltration and transforming growth factor-? production. Pirfenidone dampened splenic germinal center B-cell and T-follicular helper cell frequencies that collaborate to produce antibody. In both a minor histocompatibility antigen-mismatched as well as a MHC-haploidentical model of sclerodermatous cGVHD, pirfenidone significantly reduced macrophages in the skin, although clinical improvement of scleroderma was only seen in one model. In vitro chemotaxis assays demonstrated that pirfenidone impaired macrophage migration to monocyte chemoattractant protein-1 (MCP-1) as well as IL-17A, which has been linked to cGVHD generation. Taken together, our data suggest that pirfenidone is a potential therapeutic agent to ameliorate fibrosis in cGVHD. |*Hematopoietic Stem Cell Transplantation [MESH] |Allografts [MESH] |Animals [MESH] |B-Lymphocytes/immunology/pathology [MESH] |Bronchiolitis Obliterans/genetics/immunology/pathology/prevention & control [MESH] |Chemokine CCL2/genetics/immunology [MESH] |Disease Models, Animal [MESH] |Graft vs Host Disease/genetics/immunology/pathology/*prevention & control [MESH] |Interleukin-17/genetics/immunology [MESH] |Macrophages/*immunology/pathology [MESH] |Mice [MESH] |Mice, Mutant Strains [MESH] |Pulmonary Fibrosis/genetics/immunology/pathology/prevention & control [MESH] |Pyridones/*pharmacology [MESH] |Skin Diseases/genetics/immunology/pathology/*prevention & control [MESH] |T-Lymphocytes, Helper-Inducer/immunology/pathology [MESH]Pirfenidone ameliorates murine chronic GVHD through inhibition of macr(epmc).pdf DeepDyve Pubget Overpricing